Adaptive Biotechnologies (ADPT) EPS (Weighted Average and Diluted) (2020 - 2025)
Adaptive Biotechnologies (ADPT) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.09 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) rose 59.09% to -$0.09 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.4 through Dec 2025, up 62.96% year-over-year, with the annual reading at -$0.39 for FY2025, 63.89% up from the prior year.
- EPS (Weighted Average and Diluted) hit -$0.09 in Q4 2025 for Adaptive Biotechnologies, down from $0.06 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.06 in Q3 2025 to a low of -$0.48 in Q4 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.3 across 5 years, with a median of -$0.33 in 2023.
- Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 71.43% in 2023 and later skyrocketed 127.27% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.44 in 2021, then soared by 36.36% to -$0.28 in 2022, then plummeted by 71.43% to -$0.48 in 2023, then surged by 54.17% to -$0.22 in 2024, then surged by 59.09% to -$0.09 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for ADPT at -$0.09 in Q4 2025, $0.06 in Q3 2025, and -$0.17 in Q2 2025.